NLS Pharmaceutics Ltd, a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders, is pleased to announce the submission of three research abstracts to the 2025 Annual Meeting of the American Society of Clinical Psychopharmacology (ASCP).

The ASCP Annual Meeting, taking place from May 27 to May 30, 2025, at the Fairmont Scottsdale Princess in Scottsdale, Arizona, is one of the world’s leading conferences dedicated to advancing research in neuropsychopharmacology. This prestigious event provides a platform for cutting-edge research and innovative therapeutic approaches in neuropsychiatric drug development, precision psychiatry, and addiction medicine.

Health Technology Insights: 49 HCA Healthcare Hospitals Recognized as “America’s Best Hospitals” by Healthgrades

NLS Submitted Research Abstracts:

  1. Evaluating the Effects of Mazindol on Fentanyl Dependence in Animal Models (Study KO-943)
    This study explores the therapeutic potential of Mazindol ER, a triple monoamine reuptake inhibitor with additional activity on 5-HT1A, MOP, and OX2R receptors, for fentanyl dependence. Preclinical data will demonstrate its ability to mitigate reward-seeking behavior and withdrawal symptoms, positioning it as a promising non-opioid alternative for managing fentanyl addiction.
  2. Non-Sulfonamide Dual Orexin Receptor Agonists: Preliminary Results of AEX-41 and AEX-2 in a Mouse Model of Narcolepsy
    This research presents promising preclinical findings on AEX-41 and AEX-2, two novel dual orexin receptor agonists (DOXA), in a mouse model of narcolepsy. In preliminary conclusion, these compounds exhibit wake-promoting properties without the adverse metabolic effects associated with traditional stimulants, making them strong candidates for treating narcolepsy and related hypersomnolence disorders.
  3. Comprehensive Multitarget Strategy for Managing Diabetes-Associated Neurological and Sleep Disorders (DANS)
    This study introduces an innovative pharmacological platform for treating diabetes-related cognitive and sleep disorders. The research integrates dual orexin receptor agonists (DOXA), neuropeptide-based preconditioning, and metabolic modulators to address the interplay between neuroinflammation, β-cell dysfunction, and circadian rhythm disruption.

Health Technology Insights: ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA

Advancing Clinical Research in Neuropsychopharmacology
“NLS Pharmaceutics is honored to contribute to the 2025 ASCP Annual Meeting, one of the premier global platforms for advancing clinical research in neuropsychopharmacology,” said Dr. Eric Konofal, MD, PhD, Chief Scientific Officer of NLS Pharmaceutics. “Our research spans innovative therapeutic solutions such as Mazindol ER for fentanyl dependence, dual orexin receptor agonists for narcolepsy, and a multitarget approach to managing diabetes-related neurological and sleep disorders. These abstracts reflect our commitment to addressing critical unmet medical needs in addiction medicine, sleep disorders, and cognitive health.”

Health Technology Insights: Siolta Therapeutics and Cowellnex Enter Joint Research Agreement

To participate in our interviews, please write to our HealthTech Media Room at news@intentamplify.com

Source – prnewswire